Literature DB >> 16141323

Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.

Niklas Feldhahn1, Paula Río, Bonaventure Ndikung Bejeng Soh, Stefanie Liedtke, Mieke Sprangers, Florian Klein, Peter Wernet, Hassan Jumaa, Wolf-Karsten Hofmann, Helmut Hanenberg, Janet D Rowley, Markus Müschen.   

Abstract

Bruton's tyrosine kinase (BTK) deficiency results in a differentiation block at the pre-B cell stage. Likewise, acute lymphoblastic leukemia cells are typically arrested at early stages of B cell development. We therefore investigated BTK function in B cell precursor leukemia cells carrying a BCR-ABL1, E2A-PBX1, MLL-AF4, TEL-AML1, or TEL-PDGFRB gene rearrangement. Although somatic mutations of the BTK gene are rare in B cell precursor leukemia cells, we identified kinase-deficient splice variants of BTK throughout all leukemia subtypes. Unlike infant leukemia cells carrying an MLL-AF4 gene rearrangement, where expression of full-length BTK was detectable in only four of eight primary cases, in leukemia cells harboring other fusion genes full-length BTK was typically coexpressed with kinase-deficient variants. As shown by overexpression experiments, kinase-deficient splice variants can act as a dominant-negative BTK in that they suppress BTK-dependent differentiation and pre-B cell receptor responsiveness of the leukemia cells. On the other hand, induced expression of full-length BTK rendered the leukemia cells particularly sensitive to apoptosis. Comparing BTK expression in surviving or preapoptotic leukemia cells after 10-Gy gamma radiation, we observed selective survival of leukemia cells that exhibit expression of dominant-negative BTK forms. These findings indicate that lack of BTK expression or expression of dominant-negative splice variants in B cell precursor leukemia cells can (i) inhibit differentiation beyond the pre-B cell stage and (ii) protect from radiation-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141323      PMCID: PMC1201599          DOI: 10.1073/pnas.0505196102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity.

Authors:  Sabine Middendorp; Gemma M Dingjan; Alex Maas; Katarina Dahlenborg; Rudolf W Hendriks
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

2.  Double-strand signal sequence breaks in V(D)J recombination are blunt, 5'-phosphorylated, RAG-dependent, and cell cycle regulated.

Authors:  M Schlissel; A Constantinescu; T Morrow; M Baxter; A Peng
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

3.  Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells.

Authors:  H Hanenberg; K Hashino; H Konishi; R A Hock; I Kato; D A Williams
Journal:  Hum Gene Ther       Date:  1997-12-10       Impact factor: 5.695

4.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells.

Authors:  H Hanenberg; X L Xiao; D Dilloo; K Hashino; I Kato; D A Williams
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

5.  Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.

Authors:  E Holinski-Feder; M Weiss; O Brandau; K B Jedele; B Nore; C M Bäckesjö; M Vihinen; S R Hubbard; B H Belohradsky; C I Smith; A Meindl
Journal:  Pediatrics       Date:  1998-02       Impact factor: 7.124

6.  Foamy virus capsids require the cognate envelope protein for particle export.

Authors:  T Pietschmann; M Heinkelein; M Heldmann; H Zentgraf; A Rethwilm; D Lindemann
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.

Authors:  Patricia A Goodman; Carla M Wood; Alexei O Vassilev; Chen Mao; Fatih M Uckun
Journal:  Leuk Lymphoma       Date:  2003-06

8.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

Authors:  W S Pear; J P Miller; L Xu; J C Pui; B Soffer; R C Quackenbush; A M Pendergast; R Bronson; J C Aster; M L Scott; D Baltimore
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

9.  BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells.

Authors:  F M Uckun; K G Waddick; S Mahajan; X Jun; M Takata; J Bolen; T Kurosaki
Journal:  Science       Date:  1996-08-23       Impact factor: 47.728

10.  The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells.

Authors:  Florian Klein; Niklas Feldhahn; Lana Harder; Hui Wang; Maria Wartenberg; Wolf-Karsten Hofmann; Peter Wernet; Reiner Siebert; Markus Müschen
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

Review 2.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

3.  Are patients with X-linked agammaglobulinemia at increased risk of developing acute lymphoblastic leukemia?

Authors:  Mary Ellen Conley
Journal:  J Clin Immunol       Date:  2015-01-29       Impact factor: 8.317

Review 4.  Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Authors:  Markus Müschen
Journal:  Nat Rev Cancer       Date:  2018-01-05       Impact factor: 60.716

Review 5.  It Takes Three Receptors to Raise a B Cell.

Authors:  Kaitlin C McLean; Malay Mandal
Journal:  Trends Immunol       Date:  2020-05-22       Impact factor: 16.687

6.  Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells.

Authors:  Ronghua Hu; Yan Yan; Qinghua Li; Yani Lin; Weina Jin; Huawen Li; Ying Lu; Tianxiang Pang
Journal:  Int J Hematol       Date:  2010-06-11       Impact factor: 2.490

7.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

8.  Pre-B cell receptor signaling in acute lymphoblastic leukemia.

Authors:  Rahul Nahar; Markus Müschen
Journal:  Cell Cycle       Date:  2009-12-09       Impact factor: 4.534

9.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

10.  Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling.

Authors:  Richard G James; Travis L Biechele; William H Conrad; Nathan D Camp; Daniel M Fass; Michael B Major; Karen Sommer; XianHua Yi; Brian S Roberts; Michele A Cleary; William T Arthur; Michael MacCoss; David J Rawlings; Stephen J Haggarty; Randall T Moon
Journal:  Sci Signal       Date:  2009-05-26       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.